Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Vaccines Row, Sanofi Invests In France, Macron To Secure Supplies

CEO Restates Commitment To France

Executive Summary

Sanofi’s €610m investment helps row to be forgotten – though Macron will ‘place bets’ on several COVID-19 vaccines, not just France’s homegrown candidate.

You may also be interested in...



Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed

Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.

Sanofi Confirms Up To 1,680 Job Losses In Europe

The layoffs are part of its bid to cut costs outlined in December.

Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact

Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel